China's consumer prices fall for third month in April, PPI slips again
A prolonged housing market downturn, high household debt and job insecurity have hampered investment and consumer spending, keeping deflationary pressures alive. The economy is also facing increasing external risks from escalating trade barriers.
However, there are hopes for a de-escalation of tensions as US-China trade talks begin in Switzerland on Saturday.
The consumer price index edged down 0.1 per cent last month from a year earlier, matching a 0.1 per cent drop in March, National Bureau of Statistics data showed on Saturday, and a Reuters poll forecast of a 0.1 per cent dip.
CPI was up 0.1 per cent month-on-month versus the 0.4 per cent fall in March and compared with economists' forecasts for no change in prices.
Core inflation, excluding volatile food and fuel prices, stood at 0.5 per cent in April from a year earlier, in line with the increase recorded in March.
As the trade war between the world's two largest economies weighs on exports, China's retail giants, including JD.com and Alibaba-owned Freshippo, have initiated measures to help exporters pivot to the domestic market. This could further depress prices as business and consumer confidence remain subdued due to the uncertain outlook.
Global investment banks, including Goldman Sachs, have lowered their GDP forecasts for China this year to below the official target of around 5 per cent, attributing the downgrade to the damaging trade war.
The producer price index (PPI) dropped 2.7 per cent in April year on year, worse than a 2.5 per cent decline in March but was less than economists' forecast for a 2.8 per cent fall. REUTERS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Times
14 minutes ago
- Business Times
US: S&P 500, Nasdaq hit record highs at open on September rate cut hopes
[NEW YORK] Wall Street's main indexes opened higher on Wednesday (Aug 13) with the benchmark S&P 500 and the Nasdaq hitting record highs, underpinned by growing optimism that the Federal Reserve could restart its monetary policy easing cycle next month. The Dow Jones Industrial Average rose 112.9 points, or 0.25 per cent, at the open to 44,571.53. The S&P 500 rose 16.9 points, or 0.26 per cent, to 6,462.67, while the Nasdaq Composite rose 82.6 points, or 0.38 per cent, to 21,764.548. REUTERS
Business Times
43 minutes ago
- Business Times
Food Empire reports net loss of US$1.5 million, declares first-ever interim dividend of S$0.03
[SINGAPORE] Food Empire reported a net loss of US$1.5 million for the first half-year ended Jun 30, the group said in a bourse filing on Wednesday (Aug 13). This resulted from a US$32.6 million fair value loss on redeemable exchangeable notes issued by the company, as its share price rose significantly from the level at which the notes can be exchanged for shares. 'Mark-to-market adjustments to the redeemable exchange notes are required to be recognised in the group's interim consolidated income statement, even though they are non-cash and do not reflect operating performance,' Food Empire said. Loss per share in H1 2025 stood at US$0.0027, a reversal from earnings per share of US$0.0449 in H1 2024. Excluding the fair value loss, Food Empire's net profit after tax stood at US$31.5 million in H1 2025. This represents a 35.7 per cent increase compared to the year-ago period, on the back of higher revenue and gross margins across most core segments. Revenue rose 21.7 per cent to US$274.1 million in H1, from US$225.2 million previously. Cost of sales also grew, by 16.7 per cent to US$183.9 million from US$157.6 million in the year-ago period. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Group chief executive officer Sudeep Nair said Food Empire is 'on track to deliver yet another record-breaking performance in FY2025, barring unforeseen circumstances'. 'Our optimism is underpinned by the strength and leading position of our brands across all our markets as we continue to deliver robust results from our brand-building efforts,' he added. Food Empire declared an interim dividend for the first time, 'as a demonstration of strong business confidence'. The dividend of S$0.03 per share will be paid out on Sep 10. Growth in core segments For H1, the group said its Russia segment generated the highest revenue among its core segments, delivering a 21.6 per cent increase in sales to US$82.8 million. 'This was mainly due to price gains coupled with appreciation of the Russian ruble against the US dollar. In local currency terms, revenue rose by 17 per cent,' it added. Vietnam, its fastest-growing market, generated more than 60 per cent of the contributions from South-east Asia. The segment recorded US$77.5 million in revenue. Revenue from the group's Ukraine, Kazakhstan and Commonwealth of Independent States segment grew 19.4 per cent to US$68.4 million. This was due mainly to price gains and increased sales volumes from certain markets. The group's South Asia segment reported revenue of US$37 million, 25.1 per cent higher than in H1 2024. This was attributed to strong demand for both freeze-dried and spray-dried soluble coffee. Food Empire said its current project pipeline includes its first coffee-mix manufacturing facility in Kazakhstan in Central Asia, which is expected to be completed by the end of the year. In India, the expansion of its spray-dried soluble coffee manufacturing facility by 2027 will increase the facility's capacity by 60 per cent. A new freeze-dried soluble coffee manufacturing facility will open in Vietnam in 2028. Shares of Food Empire closed flat S$2.40 on Wednesday, before the announcement.
Business Times
3 hours ago
- Business Times
Singapore's KPB Biosciences fails in bid to unfreeze assets in US$830 million Novo Nordisk legal battle
[SINGAPORE] Locally headquartered biotech firm KPB Biosciences has failed to set aside a court order for its assets to be frozen, with the Singapore International Commercial Court (SICC) having dismissed its application on Tuesday (Aug 12). The worldwide freezing order had been obtained by Danish drugmaker Novo Nordisk, which is claiming up to S$830 million in damages from KPB, over allegations that the Singapore-based biotech firm had misled it about a drug for hypertension and kidney disease. Novo Nordisk had acquired the drug from KBP in late 2023 in a deal worth up to US$1.3 billion. But less than a year later, the pharmaceutical giant halted clinical trials because the treatment was proven to be ineffective. Novo Nordisk, best known for Ozempic, the blockbuster diabetes drug, subsequently announced an impairment loss of around US$800 million. In February, Judge Philip Jeyaretnam granted the worldwide freezing order in support of the suit, which is being arbitrated in New York. The judge determined there was a real risk that KBP would place its assets beyond Novo's legal reach. Transfers of US$339.1 million from KBP to its holding company, as well as US$578.5 million paid out in dividends, indicate that its founder, Huang Zhenhua, had the intention of moving assets out of Novo's reach in anticipation of a claim, he said. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up The freeze encompasses KBP's Singapore-based assets, which include the company's DBS fixed deposit account containing US$218 million as of Dec 31, 2023, and Huang's Sennett Estate property, valued at US$7 million at purchase. The case at hand KPB had sought to set aside the freeze order on four main grounds: It argued that Novo lacked a strong legal case, and that there was no real risk of asset misuse; it further argued that Novo had failed to provide full and frank disclosure of the freeze order. The company's lawyers also contended that the application did not satisfy the legal requirements under Section 12A of the International Arbitration Act 1994, which allows the Court to grant interim measures supporting international arbitration proceedings. But in his judgement, Judge Jeyaratnam found that Novo had a good arguable case, as the evidence sufficiently established that both KBP and Huang had misled it on the efficacy of its kidney-disease drug. He also ruled that the risk that KBP and Huang would move the assets out of Novo's reach was real. The monies Huang received have remained in his personal bank accounts. But when viewed in the context of Novo's lawsuit against KBP, these funds were found to have passed through multiple intermediaries before reaching him. The evidence thus suggested that Huang had expected Novo to file claims against KBP, but not against him personally. As for whether Novo's application fulfilled Section 12A, the judge said the requirements were established as the emergency arbitrator could not grant the freezing order, which was sought without notifying the other party to prevent asset transfers. For these and other reasons, the Court declined to set aside the freeze order. Who is KBP's founder Huang Zhenhua? The native of Shandong, China, now a Singaporean citizen, has been described in the media as a 'serial entrepreneur', with more than 20 years' experience in drug research and development. After earning his PhD from Shenyang Pharmaceutical University, he founded Xuanzhu Biopharm in 2002. A decade later, he sold it to Sihuan Pharmaceutical Holdings. He served as executive director and shareholder at Sihuan before it delisted from the SGX in 2009 and then relisted in Hong Kong the following year. Huang established KBP in 2011 in Shandong. Court documents show he owns a 40 per cent stake in the company, now incorporated in Singapore, with its global headquarters in International Plaza on Anson Road, and its operations in China and the US.
